1. Home
  2. SCYX vs OPAD Comparison

SCYX vs OPAD Comparison

Compare SCYX & OPAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCYX
  • OPAD
  • Stock Information
  • Founded
  • SCYX 1999
  • OPAD 2015
  • Country
  • SCYX United States
  • OPAD United States
  • Employees
  • SCYX N/A
  • OPAD N/A
  • Industry
  • SCYX Biotechnology: Pharmaceutical Preparations
  • OPAD Real Estate
  • Sector
  • SCYX Health Care
  • OPAD Finance
  • Exchange
  • SCYX Nasdaq
  • OPAD Nasdaq
  • Market Cap
  • SCYX 28.5M
  • OPAD 25.3M
  • IPO Year
  • SCYX 2014
  • OPAD N/A
  • Fundamental
  • Price
  • SCYX $0.71
  • OPAD $1.31
  • Analyst Decision
  • SCYX
  • OPAD Hold
  • Analyst Count
  • SCYX 0
  • OPAD 5
  • Target Price
  • SCYX N/A
  • OPAD $2.38
  • AVG Volume (30 Days)
  • SCYX 115.9K
  • OPAD 128.8K
  • Earning Date
  • SCYX 08-07-2025
  • OPAD 08-04-2025
  • Dividend Yield
  • SCYX N/A
  • OPAD N/A
  • EPS Growth
  • SCYX N/A
  • OPAD N/A
  • EPS
  • SCYX N/A
  • OPAD N/A
  • Revenue
  • SCYX $2,630,000.00
  • OPAD $794,159,000.00
  • Revenue This Year
  • SCYX $463.61
  • OPAD N/A
  • Revenue Next Year
  • SCYX $310.80
  • OPAD $40.79
  • P/E Ratio
  • SCYX N/A
  • OPAD N/A
  • Revenue Growth
  • SCYX N/A
  • OPAD N/A
  • 52 Week Low
  • SCYX $0.66
  • OPAD $0.91
  • 52 Week High
  • SCYX $2.29
  • OPAD $5.13
  • Technical
  • Relative Strength Index (RSI)
  • SCYX 39.58
  • OPAD 67.20
  • Support Level
  • SCYX $0.70
  • OPAD $0.91
  • Resistance Level
  • SCYX $0.75
  • OPAD $1.14
  • Average True Range (ATR)
  • SCYX 0.05
  • OPAD 0.12
  • MACD
  • SCYX 0.00
  • OPAD 0.05
  • Stochastic Oscillator
  • SCYX 28.80
  • OPAD 63.49

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About OPAD Offerpad Solutions Inc.

Offerpad Solutions Inc provides a way to buy and sell a home. It uses technology-enabled solutions to remake the home selling and buying experience by offering customers the convenience, control, and certainty to solve their housing needs. It combines fundamental real estate expertise with the data-driven digital Solutions Center platform to efficiently sell and buy their homes online with streamlined access to other services including mortgage, listing, renovation and buyer representation services.

Share on Social Networks: